Trial Profile
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Abacavir (Primary) ; Atazanavir (Primary) ; Darunavir (Primary) ; Didanosine (Primary) ; Emtricitabine (Primary) ; Lamivudine (Primary) ; Lamivudine/abacavir (Primary) ; Lamivudine/zidovudine (Primary) ; Ritonavir (Primary) ; Stavudine (Primary) ; Tenofovir (Primary) ; Zidovudine (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SUPPRESS
- 09 Nov 2023 Planned End Date changed from 1 Aug 2014 to 31 Aug 2014.
- 09 Nov 2023 Planned primary completion date changed from 1 Aug 2014 to 31 Aug 2014.
- 09 Nov 2023 Planned initiation date changed from 1 Jun 2012 to 30 Jun 2012.